Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
C. Shen(University of North Carolina at Chapel Hill), A.J. Rosenberg(University of Chicago), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute), William Stokes(Emory University), T. Hackman(University of North Carolina at Chapel Hill), Jessica M. Frakes(Moffitt Cancer Center), Omar I. Vivar(Nanobiotix (France)), Kedar Kirtane(Moffitt Cancer Center), Nabil F. Saba(Emory University), Po‐Cheng Chang(University of Chicago), Z. Gooi(University of Chicago), Matthias Löhr(Karolinska University Hospital), A. Juloori(University of Chicago), Jessica Weiss(University of Toronto), D Rolando(Nanobiotix (France)), G.Q. Yang(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Septimiu Murgu(University of Chicago), Joey Wing Yan Chan(Chinese University of Hong Kong)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2025
Cited by 1
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Head and neck cancer
|The Lancet|2021|829
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653